Takeda Pharma Exec Discloses Initial Ownership of 3,000 Shares
TAKEDA PHARMACEUTICAL CO LTD
Subscribe to track TAK
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Takeda Pharma Exec Discloses Initial Ownership of 3,000 Shares
Company: TAKEDA PHARMACEUTICAL CO LTD (TAK) Form: 3 | Filed: 2026/03/18 Significance: Low
Insider: Miyabashira Asuka Title: President, Japan Pharma B.U. | Relationship: Officer
Transaction: • Type: Initial Statement of Beneficial Ownership • Security: Ordinary Shares • Holdings Reported: 3,000 • Derivative Interest: Tax Obligation Awards (2,260 equiv. shares)
Key Insight: New insider reporting establishes baseline ownership; holdings are nominal relative to company size.
Market Context: Routine compliance filing for officer designation; no market-moving transaction occurred.
Comprehensive Analysis
SEC Filing Analysis: TAKEDA PHARMACEUTICAL CO LTD (TAK)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Newly appointed reporting officer establishes initial beneficial ownership baseline.
- Market Impact: Neutral - Routine compliance filing with no immediate market effect.
Company Information
| Field | Value |
|---|---|
| Company | TAKEDA PHARMACEUTICAL CO LTD |
| Ticker Symbol | TAK |
| CIK | 0001395064 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Miyabashira Asuka |
| CIK | 0002111457 |
| Title/Position | President, Japan Pharma B.U. |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 3 (Initial Statement) |
| Transaction Date | 2026-03-18 |
| Security Type | Ordinary Shares |
| Shares Reported | 3,000 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Shares Reported | 3,000 |
| % of Shares Outstanding | ~0.0002% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a massive market capitalization ($8,979B), this individual's holding is negligible from a control perspective.
- Ownership Concentration: The reporting person holds a microscopic fraction of the 1.59 billion shares outstanding.
- Dilution Impact: None. This is a report of existing holdings, not a new issuance.
- Transaction Significance: This is a Form 3, which indicates a person has become an insider (officer/director), not that they have actively bought or sold shares on the open market today.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The filing merely discloses the initial holdings of a new insider. The volume of shares (3,000) is immaterial to the stock's liquidity or price action.
Volume & Sentiment
- Expected Volume Impact: None.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Derivatives: The insider also holds "Tax Obligation Awards" equivalent to 2,260 shares, vesting between 2026 and 2028. These are cash-settled instruments used primarily to cover tax liabilities.
- Restricted Stock: The 3,000 ordinary shares reported include 1,600 Restricted Stock Units (RSUs) vesting annually from 2026 to 2028.
- New Insider: Asuka Miyabashira appears to be a newly designated Section 16 officer (President, Japan Pharma B.U.), triggering this initial disclosure.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.